Eicosanoids in asthma

Acta Paediatrica Taiwanica

Volumn 48, Issue 6, 2007, Pages 299-304

  Wan, Kong Sang ^a   Wu, Wei Fong ^a  

^a TAIPEI CITY HOSPITAL   (Taiwan)

Author keywords

Asthma; Cysteinyl leukotreine; Eicosanoid; Lipoxin; Prostaglandin

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; CORTICOSTEROID; CYSTEINYL LEUKOTRIENE RECEPTOR 1; FLUTICASONE; GELATINASE B; GLUCOCORTICOID; ICOSANOID; INTERLEUKIN 8; LEUKOTRIENE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXIN; LIPOXIN A; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ASTHMA; BRONCHOSPASM; CELL PROLIFERATION; CHEMOTAXIS; COLLAGEN SYNTHESIS; DRUG MECHANISM; DRUG POTENTIATION; EPITHELIUM CELL; FIBROBLAST; HOMEOSTASIS; HUMAN; IMMUNOMODULATION; LIPOGENESIS; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW;

ASTHMA; EICOSANOIDS; HUMANS; LEUKOTRIENES; LIPOXINS; PROSTAGLANDINS;

EID: 42149109633     PISSN: 16088115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Levy BD. Lipoxins and lipoxin analogs in asthma prostaglandins, Leukot Essent Fatty Acids 2005; 73:231-7.
2. Anonymous. Proceedings of the ATS Workshop on Refractory Asthma: current understanding, recommendations, and unanswered questions. American Throacic Society. Am J Respir Crit Care Med 2000; 162:2341-51.
3. Samuelsson B. From studies of biochemical mechanisms to novel biological mediators: prostaglandin endoperoxides, thromboxanes and leukotrienes. Les Prix Nobel: Nobel Prizes, presentations, biographies and lectures. Stockholm: Almqvist and Wiksell, 1982; 153-74.
4. Kudo I, Murakami M. Phospholipase A2 enzymes. Prostaglandins Other Lipid Mediat 2002; 68-69:3-58.
5. Uhl W, Nevalainen TJ, Buchler MW. Phospholipase A2: basic and clinical aspects in inflammatory diseases. Basel: Karger, 1997.
6. Bowton DL, Dmitrienko AA, Israel E, et al. Impact of a soluble phospholipase A2 inhibitor on inhaled allergen challenge in subjects with asthma. J Asthma 2005; 42:65-71.
7. Bradley JD, Dmitrienko AA, Kivitz AJ, et al. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol 2005; 32:417-23.
8. Kumin M, Hamberg M, Granstrom E, et al. 15(S)-hydroxyeicosatetraenoic acid is the major arachidonic acid metabolite in human bronchi: association with airway epithelium. Arch Biochem Biophys 1990; 282:254-62.
9. Chu HW, Balzar S, Westcott JY, et al. Expression and activation of 15-lipoxygenase pathway in severe asthma: relationship to eosinophil phenotype and collagen deposition. Clin Exp Allergy 2002; 32:1558-65.
10. Holgate ST, Burns GB, Robinson C, et al. Anaphylactic- and calcium-dependent generation of prostaglandin D2, thromboxane B2, and other cyclooxygenase products of arachidonic acid by dispersed human lung cells and relationship to histamine release. J Immunol 1984; 133:2138-44.
11. Kroegel C, Matthys H. Platelet-activating factor-induced human eosinophil activation: generation and release of cyclooxygenase metabolites in human blood eosinophils from asthmatics. Immunology 1993; 78:279-85.
12. Liu MC, Bleecker ER, Lichtenstein LM, et al. Evidence for elevated levels of histamine, prostaglandin D2 and other bronchoconstricting prostaglandins in the airways of subjects with mild asthma. Am Rev Respir Dis 1990; 142:126-32.
13. Tanaka K, Ogawa K, Sugamura K, et al. Cutting edge: differential production of prostaglandin D2 by human helper T-cell subsets. J Immunol 2000; 164:2277-80.
14. Kumlin M. Measurement of leukotrienes in humans. Am J Respir Crit Care Med 2000; 161:S102-6.
15. Fujitani Y, Kanaoka Y, Aritake K, et al. Pronounced eosinophilic lung inflammation and Th2 cytokine release in human lipocalin-type prostaglandin D synthase transgenic mice. J Immunol 2002; 168:443-9.
16. Murray JJ, Tonnel AB, Brash AR, et al. Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med 1986; 315:800-4.
17. Bochenek G, Nizankowska E, Gielicz A, et al. Plasma 9alpha, 11beta-PGF2, a PGD2 metabolite, as a sensitive marker of mast cell activation by allergen in bronchial asthma. Thorax 2004; 59:459-64.
18. Fuller RW, Dixon CM, Dollery CT, et al. Prostaglandin D2 potentiates airway responsiveness to histamine and methacholine. Am Rev Respir Dis 1986; 133:252-4.
19. Peters SP, Schulman RP, Schleimer DW, et al. Dispersed human lung mast cells. Pharmacologic aspects and comparison with human lung tissue fragments. Am Rev Respir Dis 1982; 126:1034-9.
20. Kita H, Abu-Ghazaleh, Gleich GJ, et al. Regulation of Ig-induced eosinophil degranulation by adenosine 3′, 5′-cyclic monophosphate. J Immunol 1991; 146:2712-8.
21. Alam R, Dejarnatt A, Stafford S, et al. Selective inhibition of the cutaneous late but not immediate allergic response to antigens by misoprostol, a PGE analog: results of a double-blind, placebo-controlled randomized study. Am Rev Respir Dis 1993; 148:1066-70.
22. Gauvreau GM, Watson RM, O'Byme PM. Protective effects of inhaled PGE2 on allergen-induced airway responses and airway inflammation. Am J Respir Crit Care Med 1999; 159:31-6.
23. Melillo E, Woolley KL, Manning PJ, et al. Effect of inhaled PGE2 on exercise-induced bronchoconstriction in asthmatic subjects. Am J Respir Crit Care Med 1994; 149:1138-41.
24. Mastalerz L, Sanak M, Gawlewicz-Mroczka A, et al. Prostaglandin E2 systemic production in asthma patients with and without aspirin hypersensitivity. Thorax 2007 Jun 21; [Epub ahead of print].
25. Pene J, Rousset F, Briere F, et al. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc Natl Acad Sci U S A 1988; 85:6880-4.
26. Khan MM. Regulation of IL-4 and IL-5 secretion by histamine and PGE2. Adv Exp Med Biol 1995; 383:35-42.
27. Gardiner PJ, Collier HO. Specific receptors for prostaglandins in airways. Prostaglandins. 1980; 19:819-41.
28. Hardy CC, Bradding P, Robinson C, et al. Bronchoconstrictor and antibronchoconstrictor properties of inhaled prostacyclin in asthma. J Appl Physiol 1988; 64:1567-74.
29. Wan KS, Jaffar Z, Roberts K. A key role for prostaglandin I2 in limiting lung mucosal Th2, but not Th1, responses to inhaled allergen. J Immunol 2002; 169:5997-6004.
30. Aqo H, Kanaoka Y, Irikura D, et al. Crystal structure of a human membrane protein involved in a cysteinyl leukotriene biosynthesis. Nature 2007; 448:609-12.
31. Woszczek G, Chen LY, Naginensi S, et al. IFN-gamma induces cysteinyl leukotriene receptor 2 expression and enhances the responsiveness of human endothelial cells to cysteinyl leukotrienes. J Immunol 2007; 178:5262-70.
32. Crowther SD, Rees PJ. Current treatment of asthma: focus on leukotrienes. Expert Opin Pharmacother 2000; 1:1021-40.
33. Kim SH, Park HS. Pathogenesis of nonsteroidal antiiflammatory drug-induced asthma. Curr Opin Allergy Clin Immunol 2006; 6:17-22.
34. Capra V, Ambrosio M, Riccioni G, et al. Cysteinyl-leukotriene receptor antagonists: present situation and future opportunities. Curr Med Chem 2006; 13:3213-26.
35. Kraft M, Cairns CB, Ellison MC, et al. Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast. Chest 2006; 130:1726-32.
36. Ichiyama T, Morishima T, Kajimoto M, et al. Matrix metalloproteinase-9 and tissue inhibitors of metalloproteinases 1 in influenza-associated encephalopathy. Pediatr Infect Dis J 2007; 26:542-4.
37. Kim DC, Hsu FI, Barrett NA, et al. Cysteinyl leukotrienes regulate Th2 cell-dependent pulmonary inflammation. J Immunol 2006; 176:4440-8.
38. Can M, Yuksel B, Demirtas S, et al. The effect of montelukast on soluble interleukin-2 receptor and tumor necrosis factor alpha in pediatric asthma. Allergy Asthma Proc 2006; 27:383-6.
39. Cai C, Yang J, Hu S, et al. Relationship between urinary cysteinyl leukotriene E4 levels and clinical response to antileukotriene treatment in patients with asthma. Lung 2007; 185:105-12.
40. Rovati GE, Baroffio M, Citro S, eta l. Cysteinyl-leukotrienes in the regulation of beta2-adrenoceptor function: an in vitro model of asthma. Respir Res 2006; 7:103.
41. Gyllfors P, Dahlen SE, Kumlin M, et al. Bronchial responsiveness to leukotriene D4 is resistant to inhaled fluticasone propionate. J Allergy Clin Immunol 2006; 118:78-83. Epub 2006.
42. Bonnans C, Chanez P, Chavis C. Lipoxins in asthma: Potential therapeutic mediators on bronchial inflammation? Allergy 2004; 59:1024-41.
43. Parkinson JF. Lipoxin and synthetic lipoxin analogs: an overview of anti-inflammatory functions and new concepts in immunomodulation. Inflamm Allergy Drug Targets 2006; 5:91-106.
44. Das UN. Can perinatal supplementation of long-chain polyunsaturated fatty acids prevent atipy, bronchial asthma and other inflammatory condition? Med Sci Monit 2006; 12:99-111.
45. Ariel A, Chiang N, Arita M, et al. Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T-cells. J Immunol 2003; 170:6266-72.
46. Chiang N, Fierro IM, Gronert K, et al. Activation of lipoxin A(4) receptors by aspirin-triggered lipoxins and select peptides evokes ligand-specific responses in inflammation. J Exp Med 2000; 191:1197-208.
47. Livy BD, De Sanctis GT, Devchand PR, et al. Multipronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A(4). Nat Med 2000; 8:1018-23.
48. Bonnans C, Levy BD. Lipid mediators as agonists for the resolution of acute lung inflammation and injury [Review]. Am J Respir Cell Mol Biol 2007; 36:201-5.
49. Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, et al. 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med 2004; 200:69-78.